Company: NDRA
Filing Date: 2025-11-26
Form Type: 424B4
Source: 0001213900-25-115097
Chunk: 4

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-26
Form: 424B4
Chunk 4
---
 factors that may cause actual results to differ materially from those indicated in
the forward-looking statements include, among others, the following:

| ● | our                                                                
 limited commercial experience, limited cash and history of losses; |

| ● | our                                                                                 
 ability to obtain adequate financing to fund our business operations in the future; |

| ● | our                               
 ability to achieve profitability; |

| ● | delays                                                                                    
 and changes in regulatory requirements, policy and guidelines, including potential delays 
 in submitting required regulatory applications or other submissions with respect to U.S.  
 Food and Drug Administration (“FDA”) or other regulatory agency approval;                 |

| ● | our                                                                                              
 ability to obtain CE mark certification and secure required FDA and other governmental approvals 
 for our Thermo-Acoustic Enhanced Ultrasound (“TAEUS”) applications                               |

| ● | our                                                                                   
 ability to develop a commercially feasible application based on our TAEUS technology; |

| ● | market                        
 acceptance of our technology; |

| ● | the                                                 
 effect of macroeconomic conditions on our business; |

| ● | results                                                      
 of our human studies, which may be negative or inconclusive; |

| ● | our                                                
 ability to find and maintain development partners; |

| ● | our                                                                                       
 reliance on third parties, collaborations, strategic alliances and licensing arrangements 
 to complete our business strategy;                                                        |

| ● | the                                               
 amount and nature of competition in our industry; |

| ● | our                                           
 ability to protect our intellectual property; |

| ● | potential                                                                  
 changes in the healthcare industry or third-party reimbursement practices; |

| ● | our                                                                                         
 ability to comply with regulation by various federal, state, local and foreign governmental 
 agencies and to maintain necessary regulatory clearances or approvals;                      |

| ● | our                                                           
 ability to maintain compliance with Nasdaq listing standards; |

| ● | our                                                                                   
 ability to successfully adopt and execute on our new digital asset treasury strategy; |

| ● | risks                                                                                        
 related to regulatory developments regarding digital assets and digital asset markets, which 
 could adversely affect our business, financial condition, and results of operations;         |

| ● | the                                                              
 volatile and unpredictable cycles in the digital asset industry; |

| ● | any                                                    
 changes in the accounting treatment of digital assets; |

| ● | our                                           
 dependence on our senior management team; and |

| ● | the                                                                                         
 other risks and uncertainties described in the Risk Factors section of this prospectus, any 
 prospectus supplement and our most recent Annual